Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC
The findings highlight the significant role of CYP2S1 in mediating drug resistance in certain PDAC subtypes. Targeting CYP2S1 and its regulatory pathways could enhance the efficacy of chemotherapeutic agents like irinotecan in treating PDAC. These results provide new insights into the molecular mechanisms underlying PDAC subtype-specific drug resistance and suggest potential therapeutic targets.
Authors
- Thilo Hackert (ORCID: https://orcid.org/0000-0002-7012-1196)
- Martin R. Sprick (ORCID: https://orcid.org/0000-0001-9691-7574)
- Christiane A. Opitz (ORCID: https://orcid.org/0000-0001-5575-9821)
- Manuel Reitberger
- Wiebke Nadler (ORCID: https://orcid.org/0000-0002-7673-1147)
- Nathalia A. Giese (ORCID: https://orcid.org/0000-0001-5920-3142)
- Alexander Kerner (ORCID: https://orcid.org/0000-0002-2729-4286)
- Vera Thiel (ORCID: https://orcid.org/0000-0003-2833-8911)
- Ronald Koschny (ORCID: https://orcid.org/0000-0003-2117-9137)
- Elisa M. Noll (ORCID: https://orcid.org/0000-0001-6334-129X)
- Laura Kuhlmann
- Hsi-Yu Yen (ORCID: https://orcid.org/0000-0003-2644-2782)
- Vanessa Vogel
- Andreas Trumpp (ORCID: https://orcid.org/0000-0002-6212-3466)
- Tim Vorberg
- Paul Schwerd‐Kleine
- Corinna Klein
- Katja Steiger
- Christoph Rösli
Institutions
- U.S. National Science Foundation (US)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Ta Solutions (China) (CN)
- National Cancer Institute (US)
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (DE)
- Vårdcentralen Teleborg (SE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Technical University of Munich (DE)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Pancreas
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1097/mpa.0000000000002553
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00